



**HAL**  
open science

## **Prognostic impact of phenotype heterogeneity of grade 1-2 metastatic gastroenteropancreatic neuroendocrine tumors documented by 18FDG PET-CT and 68Ga-DOTANOC PET-CT**

M. Barbaud, Yann Touchefeu, M. Le Bras, Vincent Fleury, Thomas Carlier, Clément Bailly, Eric Frampas, Aurore Rauscher, Françoise Kraeber-Bodéré, Catherine Ansquer

### ► To cite this version:

M. Barbaud, Yann Touchefeu, M. Le Bras, Vincent Fleury, Thomas Carlier, et al.. Prognostic impact of phenotype heterogeneity of grade 1-2 metastatic gastroenteropancreatic neuroendocrine tumors documented by 18FDG PET-CT and 68Ga-DOTANOC PET-CT. 33rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), European-Association-of-Nuclear-Medicine (EANM), Oct 2020, Virtuel, France. pp.S585. inserm-03498714

**HAL Id: inserm-03498714**

**<https://inserm.hal.science/inserm-03498714>**

Submitted on 21 Dec 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

usually is not connected to the real profile of somatostatin receptors expression in the tumor tissues. **Materials and Methods:** Case report: In 03.2009 a 34-years old male was referred to Endocrinology Clinic with suspicion of pancreatic NET. MRI revealed presence of a 54x42mm tumor of the distal part of the pancreas and 2 metastatic changes in the liver. Liver biopsy confirmed neuroendocrine neoplasm. Resection of the pancreatic body and tail with splenectomy was performed on 04.2009 (pathology: neuroendocrine cancer, Ki67 50%, metastases in 17/20 nodes). The tumor had good expression of somatostatin receptors (sstr) in the primary and metastatic lesions. Due to the high expression of sstr, patient received 1 dose of PRRT with the next Gemzar and Erlotinib therapy which was ended in 08.2011. From 2015, the PET/CT scan with 68GaDOTA-TATE show pathological (Krenning score 3 and 4) expression of sstr in the retropharyngeal node. The lesion had slowly progressed in various follow-up studies. In 09.2016, the conglomerate of neck nodes group II and V, the submandibular salivary gland and the node of the mandible angle were removed (metastases to lymph nodes were confirmed, Ki67 3%). The follow-up PET/CT studies with 68Ga DOTA-TATE started from 11.2016 showed the persistent pre-vertebral SSTR+ space infiltration extending from the base of the skull to level C1/C2 and involvement of cervical Ila nodes. A follow-up study with 68Ga DOTA-TOC showed only slightly elevated (Krenning score 1) expression of sstr in the pre-vertebral space (previously with high pathological expression of sstr seen on 68GaDOTA-TATE PET/CT). The next follow-up study with 68GaDOTA TATE again revealed high, pathological expression of sstr in the neck area. **Results:** Patient with pancreatic NETG3 was found to have incompatible imaging results using both 68Ga-TOC and -TATE ligands. **Conclusion:** The result of PET/CT 68Ga-somatostatin analogue imaging with different ligands may give different results in the same patient and in extreme cases may lead to the suboptimal choice of therapeutic procedures (disqualification from long-acting somatostatin analogue treatment and PRRT in case of dissemination of the disease). **References:** None

## EP-157

### Prognostic impact of phenotype heterogeneity of grade 1-2 metastatic gastroenteropancreatic neuroendocrine tumors documented by 18FDG PET-CT and 68Ga-DOTANOC PET-CT

M. Barbaud<sup>1</sup>, Y. Touchefeu<sup>2</sup>, M. Le Bras<sup>3</sup>, V. Fleury<sup>4</sup>, T. Carlier<sup>1,5</sup>, C. Bailly<sup>1,5</sup>, E. Frampas<sup>6</sup>, A. Rauscher<sup>7</sup>, F. Kraeber-Bodere<sup>1,5</sup>, C. Ansquer<sup>1</sup>;  
<sup>1</sup>Nuclear Medicine Unit, University Hospital, Nantes, FRANCE, <sup>2</sup>Digestive Oncology, Institut Des Maladies De l'Appareil Digestif, University Hospital, Nantes, FRANCE, <sup>3</sup>Department of Endocrinology, University Hospital, Nantes, FRANCE, <sup>4</sup>Nuclear Medicine Unit, Institut de Cancérologie de l'Ouest, Saint-Herblain, FRANCE, <sup>5</sup>CRCINA, INSERM, CNRS, Angers University, Nantes University, Nantes, FRANCE, <sup>6</sup>Department of Radiology,

University Hospital, Nantes, FRANCE, <sup>7</sup>Pharmacy Unit, Institut de Cancérologie de l'Ouest, Saint-Herblain, FRANCE.

**Aim/Introduction:** The identification of prognostic factors for survival in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET) represents a challenge for patient management. This retrospective study investigated the phenotype presentation of these tumors with 18FDG and 68Ga-DOTANOC-PET-CT and analyzed its prognostic impact on survival. **Materials and Methods:** Patients with metastatic histologically proven grade 1 (G1) or 2 (G2) GEP-NET (WHO 2019 classification), who underwent 18FDG-PET-CT and 68Ga-DOTANOC-PET-CT within 2 months between 2013 and 2017, were included. For 18FDG-PET-CT analysis, pathological foci which exceeded in intensity healthy liver were considered significant. Progression was assessed with clinical and radiological criteria. Progression free survival (PFS) and overall survival (OS) were evaluated. Kaplan-Meier method was used (curves being compared with log-rank test). Prognostic factors were evaluated with univariate and multivariate analysis (Cox proportional hazards model), with a p value of less than 0.05 considered significant. **Results:** A total of 39 patients (23 males, 16 females, median age: 59 years), 10 with G1 (26%) and 29 with G2 (74%) tumors were included, mainly pancreatic (n=20; 51%) or midgut (n=13; 33%) origin. Median Ki67 index was 7%, >10% in 11 patients (28%). 68Ga-DOTANOC-PET-CT was positive (at least one lesion) in 100% of patients and 18FDG-PET-CT in 72% of patients (n=28). At least one 18FDG+/68Ga-DOTANOC-lesion was found in 4 patients (10%). After a median follow-up of 39 months, 24 patients had progressive disease (64%) and 11 died (28%). PFS was significantly lower in 18FDG-PET-CT positive patients than in 18FDG-PET-CT negative patients (14vs55.9 months; p=0.0249). Furthermore, the number of 18FDG positive lesions and the presence of at least one 18FDG+/68Ga-DOTANOC-lesion were significantly correlated with PFS in univariate (respectively, p<0.0001 and p=0.007) and multivariate analysis (respectively p=0.0012 and p=0.020). Despite the low number of event, the presence of at least one 18FDG+/68Ga-DOTANOC-lesion was associated with poor OS (p=0.017). The number of previous treatment was associated with PFS in univariate analysis (p=0.0396) but not in multivariate analysis. None of the other clinical, biological (including WHO grade, Ki67 index) or 68Ga-DOTANOC-PET-CT data were significantly associated with PFS or OS. **Conclusion:** Our results showed the high prevalence of 18FDG positive lesions in G1 and G2 metastatic GEP-NET illustrating the heterogeneity of these tumors and confirmed the prognostic impact of 18FDG-PET-CT on PFS. In particular, the number of 18FDG positive lesions and the presence of at least one 18FDG+/68Ga-DOTANOC-lesion were associated with a poorer prognosis in our patients. **References:** None